Transcriptome studies of congenital heart diseases: identifying current gaps and therapeutic frontiers

• Published in: Frontiers in genetics Vol. 14; p. 1278747
• Main Authors: Odogwu, Nkechi Martina, Hagen, Clinton, Nelson, Timothy J.
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 13.12.2023
• Subjects: animal model; gene expression; Genetics; iPSC models; pediatric congenital heart disease; RNA sequencing; transcriptomes; RNA sequencing; iPSC models; pediatric congenital heart disease; transcriptomes; noncoding transcriptomes; animal model; gene expression
• ISSN: 1664-8021; 1664-8021
• DOI: 10.3389/fgene.2023.1278747

Congenital heart disease (CHD) are genetically complex and comprise a wide range of structural defects that often predispose to - early heart failure, a common cause of neonatal morbidity and mortality. Transcriptome studies of CHD in human pediatric patients indicated a broad spectrum of diverse molecular signatures across various types of CHD. In order to advance research on congenital heart diseases (CHDs), we conducted a detailed review of transcriptome studies on this topic. Our analysis identified gaps in the literature, with a particular focus on the cardiac transcriptome signatures found in various biological specimens across different types of CHDs. In addition to translational studies involving human subjects, we also examined transcriptomic analyses of CHDs in a range of model systems, including iPSCs and animal models. We concluded that RNA-seq technology has revolutionized medical research and many of the discoveries from CHD transcriptome studies draw attention to biological pathways that concurrently open the door to a better understanding of cardiac development and related therapeutic avenue. While some crucial impediments to perfectly studying CHDs in this context remain obtaining pediatric cardiac tissue samples, phenotypic variation, and the lack of anatomical/spatial context with model systems. Combining model systems, RNA-seq technology, and integrating algorithms for analyzing transcriptomic data at both single-cell and high throughput spatial resolution is expected to continue uncovering unique biological pathways that are perturbed in CHDs, thus facilitating the development of novel therapy for congenital heart disease.